Healthcare Industry News: Eli Lilly
News Release - November 24, 2010
Bausch & Lomb Names Charl van Zyl as Commercial Leader, Europe, Middle East and AfricaROCHESTER, NY--(Healthcare Sales & Marketing Network) - Bausch & Lomb, the global eye health company, has named Charl van Zyl as corporate vice president and commercial leader, Europe, Middle East and Africa (EMEA).
"Charl is a strong, strategic leader with a proven ability to drive executional excellence," said Brent Saunders, chief executive officer, Bausch & Lomb. "In this newly created role, Charl will be placing a special focus on building high-performance, customer-centric teams for our Vision Care, Pharmaceuticals and Surgical businesses in all our markets across this important region."
Mr. van Zyl will lead the company's cross-functional, multi-market EMEA operations team. He will also have direct commercial responsibility for B&L's emerging markets in the region.
Mr. van Zyl joined Bausch & Lomb in 2009, serving as vice president, EMEA, for the company's Pharmaceuticals business. In recent months he has taken on additional region-wide responsibilities.
Before coming to B&L, Mr. van Zyl was chief executive officer for Jado Technologies, the German biotechnology firm. From 2004 to 2007 he held positions at Novartis Pharma AG as head of Marketing and Sales, Pharma Europe, and head of Global Marketing, Ophthalmics. Earlier in his career he held multiple positions with Eli Lilly & Co, with responsibilities spanning across Japan, the United States, Europe and Latin America.
Mr. van Zyl graduated from the University of Cape Town with Bachelors of Science (Medicine) Honours and MBA degrees. He will be based at Bausch & Lomb's offices in Zug, Switzerland.
About Bausch & Lomb
Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected health care brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBausch & Lomb Announces the U.S. Launch of LOTEMAX(R) SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% for the Treatment of Postoperative Inflammation and Pain Following Ocular Surgery
Bausch & Lomb Receives 510(k) Clearance For Use Of The Tangible(R) Hydra-PEG(R) Custom Contact Lens Coating Technology On Several Of Its Boston(R) Gas Permeable Lens Materials And Zenlens(TM) Family Of Scleral Lenses
Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets